Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company focusing on innovative immune-oncology technologies for hard-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Jim Parslow, the company's Interim CEO and CFO, delivered a presentation at the event. The video webcast of this presentation is now available on the Events page in the Investors section of Xenetic's website (www.XeneticBio.com) and will remain accessible for 90 days.
Xenetic Biosciences (NASDAQ:XBIO), un'azienda biofarmaceutica che si concentra su tecnologie innovative di immuno-oncologia per tumori difficili da trattare, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. Jim Parslow, CEO e CFO ad interim dell'azienda, ha tenuto una presentazione durante l'evento. La diretta video di questa presentazione è ora disponibile nella pagina Eventi nella sezione Investor del sito web di Xenetic (www.XeneticBio.com) e rimarrà accessibile per 90 giorni.
Xenetic Biosciences (NASDAQ:XBIO), una empresa biofarmacéutica que se enfoca en tecnologías innovadoras de inmuno-oncología para cánceres difíciles de tratar, anunció su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. Jim Parslow, CEO y CFO interino de la empresa, realizó una presentación en el evento. La transmisión de video de esta presentación ya está disponible en la página de Eventos en la sección para Inversores del sitio web de Xenetic (www.XeneticBio.com) y seguirá accesible durante 90 días.
Xenetic Biosciences (NASDAQ:XBIO), 치료하기 어려운 암을 위한 혁신적인 면역종양학 기술에 중점을 둔 생명공학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에서의 참여를 발표했습니다. 짐 파슬로우는 회사의 임시 CEO 겸 CFO로서 이 행사에서 발표를 진행했습니다. 이 발표의 비디오 웹캐스트는 현재 Xenetic 웹사이트의 투자자 섹션의 이벤트 페이지에서 이용 가능하며 90일 동안 접근할 수 있습니다.
Xenetic Biosciences (NASDAQ:XBIO), une entreprise biopharmaceutique axée sur les technologies innovantes d'immuno-oncologie pour les cancers difficiles à traiter, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Jim Parslow, le PDG et CFO par intérim de l'entreprise, a présenté lors de l'événement. Le webcast vidéo de cette présentation est désormais disponible sur la page Événements de la section Investisseurs du site web de Xenetic (www.XeneticBio.com) et restera accessible pendant 90 jours.
Xenetic Biosciences (NASDAQ:XBIO), ein biopharmazeutisches Unternehmen, das sich auf innovative Immunonkologie-Technologien für schwer zu behandelnde Krebsarten konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Jim Parslow, der vorläufige CEO und CFO des Unternehmens, hielt eine Präsentation auf der Veranstaltung. Der Video-Webcast dieser Präsentation ist jetzt auf der Events-Seite im Investorenbereich der Xenetic-Website (www.XeneticBio.com) verfügbar und bleibt für 90 Tage zugänglich.
- Participation in a major investment conference, potentially increasing visibility to investors
- Availability of presentation webcast on company website, enhancing transparency and investor communication
- None.
FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference.
The video webcast of the presentation is now accessible on the Events page in the Investors section of the Company's website (www.XeneticBio.com) and will be archived for 90 days.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com
FAQ
What event did Xenetic Biosciences (XBIO) participate in recently?
Where can investors access Xenetic Biosciences' (XBIO) recent presentation?
How long will Xenetic Biosciences' (XBIO) presentation webcast be available?
What is Xenetic Biosciences' (XBIO) main focus as a company?
